We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
-29.05%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$207M
AUM Growth
-$32.3M
(-14%)
Cap. Flow
+$36M
Cap. Flow
% of AUM
17.4%
Top 10 Holdings %
Top 10 Hldgs %
95.02%
Holding
15
New
3
Increased
7
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$14.6M |
| 2 |
uniQure
QURE
|
+$11.4M |
| 3 |
argenx
ARGX
|
+$4.07M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$3.19M |
| 5 |
SYBX
Synlogic
SYBX
|
+$2.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$15.5M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$12.8M |
| 3 |
Fate Therapeutics
FATE
|
+$4.01M |
| 4 |
PVLA
Palvella Therapeutics
PVLA
|
+$2.96M |
| 5 |
CytomX Therapeutics
CTMX
|
+$2.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $108M | 52.09% |
1,500,000
+400,000
| +36% | +$32.2M |
|
|
MRUS
2
DELISTED
Merus
MRUS
| $20.7M | 10.03% |
1,480,855
+185,142
| +14% | +$2.68M |
|
|
3
Arrowhead Research
ARWR
$12.4B
| $13.2M | 6.4% |
+1,064,928
| New | +$14.6M |
|
|
4
uniQure
QURE
$3.22B
| $11.8M | 5.7% |
+408,729
| New | +$11.4M |
|
|
SYBX
5
DELISTED
Synlogic
SYBX
| $9.35M | 4.53% |
88,945
+22,409
| +34% | +$2.95M |
|
|
6
Fate Therapeutics
FATE
$326M
| $8.94M | 4.33% |
697,096
-287,500
| -29% | -$4.01M |
|
|
7
CytomX Therapeutics
CTMX
$754M
| $7.92M | 3.84% |
524,763
-150,000
| -22% | -$2.23M |
|
8
Spero Therapeutics
SPRO
$73M
| $6.35M | 3.07% |
1,031,947
+232,256
| +29% | +$1.88M |
|
|
9
Xenon Pharmaceuticals
XENE
$6.12B
| $6M | 2.91% |
951,527
+358,725
| +61% | +$3.19M |
|
|
10
argenx
ARGX
$54.1B
| $4.4M | 2.13% |
+45,806
| New | +$4.07M |
|
|
LOXO
11
DELISTED
Loxo Oncology, Inc
LOXO
| $3.47M | 1.68% |
24,750
-84,562
| -77% | -$12.8M |
|
|
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $3.29M | 1.59% |
35,920
+4,600
| +15% | +$466K |
|
|
PVLA
13
Palvella Therapeutics
PVLA
$2.27B
| $3.22M | 1.56% |
15,135
-9,554
| -39% | -$2.96M |
|
|
MOR
14
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $298K | 0.14% |
11,787
+2,700
| +30% | +$70.8K |
|
|
KDNY
15
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-421,056
| Closed | -$15.5M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Aquilo Capital Management held 15 positions worth $207M, down 14% from $239M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Aquilo Capital Management deployed $36M of net new capital in Q4 2018, opening 3 new positions and adding to 7 existing holdings. Its largest new stake was Arrowhead Research: 1,064,928 shares worth $13.2M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 56% a quarter earlier.
On the sell side, the largest reduction was Loxo Oncology, Inc, an estimated $12.8M trimmed.
- Aquilo Capital Management's largest Q4 2018 buy was Arrowhead Research: 1,064,928 shares worth $13.2M.
- Aquilo Capital Management added most to Xenon Pharmaceuticals in Q4 2018, an estimated $3.19M increase.
- Aquilo Capital Management's biggest Q4 2018 reduction was Loxo Oncology, Inc, cutting an estimated $12.8M.
- Aquilo Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q4 2018, selling an estimated $15.5M.
- Aquilo Capital Management's ten largest holdings make up 95% of its $207M portfolio in Q4 2018.
- Aquilo Capital Management opened 3 new positions and closed 1 in Q4 2018.
- Aquilo Capital Management's portfolio value fell 14% quarter-over-quarter to $207M.
Based on Aquilo Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.